^
    2years
    Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM) (ASH 2022)
    CYT-338 mediates potent anti- tumor activity against MM cell lines and patient tumors in the presence of effector cells (PBNK, iNK or MM patient NK cells). Evidence for additional CYT-338 effector function invoking macrophages and complement mediated MM tumor killing was obtained. Differential gene expression analysis provides mechanistic clues for a distinct cytotoxicity profile for CYT-338 from daratumumab that supports further evaluation of this potent anti-CD38 antibody.
    IO biomarker
    |
    CD38 (CD38 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • SDC1 (Syndecan 1) • CCL8 (C-C Motif Chemokine Ligand 8) • CD31 (Platelet and endothelial cell adhesion molecule 1) • CD2 (CD2 Molecule) • IFI35 (Interferon Induced Protein 35) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CD96 (CD96 Molecule) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    CD38 expression • CD38 positive
    |
    nCounter® PanCancer IO 360™ Panel
    |
    Darzalex (daratumumab) • NY-338